Kaer Biotherapeutics
Medical Devices, 926 S Andreasen Dr, Escondido, California, 92029, United States, 1-10 Employees
Who is KAER BIOTHERAPEUTICS
KAER Biotherapeutics is a preclinical aerosol drug delivery company addressing the needs of respiratory ailments in clinics and hospitals. KAER is primarily focused on the provision of su...
Read More
-
Headquarters: 926 S Andreasen Dr, Escondido, California, 92029, United States
-
Date Founded: 2008
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Medical Devices
SIC Code: 8731
|
NAICS Code: 423450 |
Show More
Does something look wrong? Fix it. | View contact records from KAER BIOTHERAPEUTICS
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding KAER Biotherapeutics
Answer: KAER Biotherapeutics's headquarters are located at 926 S Andreasen Dr, Escondido, California, 92029, United States
Answer: KAER Biotherapeutics's official website is https://kaerbio.com
Answer: KAER Biotherapeutics's revenue is Under $1 Million
Answer: KAER Biotherapeutics's SIC: 8731
Answer: KAER Biotherapeutics's NAICS: 423450
Answer: KAER Biotherapeutics has 1-10 employees
Answer: KAER Biotherapeutics is in Medical Devices
Answer: KAER Biotherapeutics contact info: Phone number: Website: https://kaerbio.com
Answer: KAER Biotherapeutics is a preclinical aerosol drug delivery company addressing the needs of respiratory ailments in clinics and hospitals. KAER is primarily focused on the provision of surfactant aerosol therapy for patients in respiratory distress related to the absence of sufficient active lung surfactant. These patients include prematurely born infants whose lungs are not producing sufficient low surface tension surfactant to enable their airways to fully open and support adequate respiratory function. Neonatal Respiratory Distress Syndrome, NRDS, is the major cause of mortality in prematurely born neonates. At any age, but especially in the elderly, insults to the lungs and body can induce acute respiratory distress. Acute respiratory distress syndrome, ARDS, results from abnormal surfactant production and inflammation-induced degradation of surfactant. When this is the result of a direct insult to the lungs, such as pneumonia or smoke inhalation, it is denoted acute lung injury, ALI. ALI can rapidly deteriorate into ARDS. There are no approved drugs for patients with ARDS. Despite the best life support, 40% of these patients die. KAER developed patented enabling aerosol generation, processing and delivery technology to address these needs. KAERs SUPRAER technology aerosolizes liquids containing the surfactant or other active pharmaceutical agent and delivers them as concentrated pure fine particle solid-phase aerosols suitable for deep lung deposition. SUPRAER is differentiated by its ability to aerosolize viscous fluids and suspensions of high molecular weight agents. High masses of fine particle therapeutic aerosols therapies can be rapidly administered at clinically relevant doses. KAER is seeking partners to facilitate the rapid implementation of this the aerosol delivery technology for the treatment of respiratory distress, IPF, hospital acquired pneumonia, TB, NSCLC and other debilitating lung diseases.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month